FDA’s ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindonews2021-09-24T15:24:03+00:00September 24th, 2021|Fierce Pharma|
Responding to global vaccine demand, Cytiva pledges $52.5M to build South Korean factorynews2021-09-24T14:48:21+00:00September 24th, 2021|Fierce Pharma|
Regeneron and Roche’s COVID drug wins WHO backing, but agency calls for lower prices and better accessnews2021-09-24T14:10:55+00:00September 24th, 2021|Fierce Pharma|
Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fightnews2021-09-24T13:44:15+00:00September 24th, 2021|Fierce Pharma|
AstraZeneca, Merck target broad use of Lynparza in prostate cancer as PARP rivals Pfizer, J&J, Clovis loomnews2021-09-24T13:34:10+00:00September 24th, 2021|Fierce Pharma|
Fierce Pharma Asia—Enhertu’s big win; Biogen-Samsung’s Lucentis biosimilar; Clover’s COVID vaccine datanews2021-09-24T09:19:22+00:00September 24th, 2021|Fierce Pharma|
CDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinibnews2021-09-23T19:42:47+00:00September 23rd, 2021|Fierce Pharma|
Takeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rulesnews2021-09-23T15:27:28+00:00September 23rd, 2021|Fierce Pharma|
Vaccine players in Argentina, Brazil selected as regional producers for COVID-19 shotsnews2021-09-23T13:55:19+00:00September 23rd, 2021|Fierce Pharma|
Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategynews2021-09-23T13:52:20+00:00September 23rd, 2021|Fierce Pharma|
